

# Pancreatic Cancer Market Global Industry Analysis 2016

---

*"Pancreatic Cancer -Pipeline Insights, 2016", report provides comprehensive insights about pipeline drugs across this indication*

PUNE, INDIA , November 16, 2016 /EINPresswire.com/ -- [Global Pancreatic Cancer Market](#)

## Summary

DelveInsight's, "Pancreatic Cancer -Pipeline Insights, 2016", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all 103 pipeline drugs that fall under the category of Pancreatic Cancer. Recent report of Delveinsight covers drugs that are being developed with novel approach to target or intervene along the pathways of tumorigenesis. Among the pipeline agents NewLink Genetics Corporation's algenpantucel-L is expected to be the frontrunner amongst all other drugs. The therapeutic candidate has also received fast Track and orphan drug designations from the FDA and is expected to launch in both the resectable and unresectable locally-advanced settings. The report also provides a comparative analysis of therapeutics based on the molecule type, route of administration, etc. It also gives insights of other activities such as, agreements, joint ventures, partnerships, acquisitions and mergers.

Try Sample Report @ <https://www.wiseguyreports.com/sample-request/476527-pancreatic-cancer-pipeline-insights-2016>

## Scope:

The new report, provides a Pancreatic Cancer Landscape across the globe

- The report provides drug profiles which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, Preclinical and Discovery stages
- Coverage of the Pancreatic Cancer pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Pancreatic Cancer and also provide company profiling
- Pipeline products coverage based on various stages of development from NDA filings to discovery.
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type.

Access Complete Report @ <https://www.wiseguyreports.com/reports/476527-pancreatic-cancer-pipeline-insights-2016>

## Reasons to Buy

Complete Pipeline intelligence and complete understanding over therapeutics development for Pancreatic Cancer

- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Pancreatic Cancer pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Table of Contents:

### Pancreatic Cancer Overview

- Pancreatic Cancer Types:
- Epidemiology:
- Market Scenario:
- Pipeline Therapeutics
- An Overview of Pipeline Products for Pancreatic Cancer
- Therapeutics under Development by Companies
- Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Mid Stage Products (Phase II)
- Comparative Analysis
- Early Stage Products (Phase I and IND)
- Comparative Analysis
- Discovery and Pre-clinical stage Products
- Comparative Analysis
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Discontinued Products
- Dormant Products
- Companies involved in Therapeutics Development
- Appendix
- Methodology
- Consulting Services
- Disclaimer
- Report Purchase Options
- About DelveInsight
- Contact Us

List of Tables:

### Table 1: Number of Products Under Development for Pancreatic Cancer 2016

- Table 2: Number of Products under Development by Companies, 2016
- Table 3: Last Stage Products (Phase III and Filed), 2016
- Table 4: Mid Stage Products (Phase II), 2016
- Table 5: Early Stage Products (Phase I and IND), 2016

- Table 6: Phase 0 stage Products, 2016
- Table 7: Discovery and Pre-clinical Stage Products, 2016
- Table 8: Assessment by Monotherapy Products, 2016
- Table 9: Assessment by Route Of Administration, 2016
- Table 10: Assessment by Stage and Route Of Administration, 2016
- Table 11: Assessment by Molecule Type, 2016
- Table 12: Assessment by Stage and Molecule Type, 2016
- Table 13: Discontinued Products, 2016
- Table 14: Dormant Products, 2016
- Table 15: Companies Involved in Therapeutic Development, 2016

List of Figures:

Figure 1: Number of Products under Development for Pancreatic Cancer, 2016

- Figure 2: Late Stage Products (Filed and Phase III), 2016
- Figure 3: Mid Stage Products (Phase II), 2016
- Figure 4: Early Stage Products (Phase I and IND), 2016
- Figure 5: Discovery and Pre-clinical Stage Products, 2016
- Figure 6: Assessment by Monotherapy Products, 2016
- Figure 7: Assessment by Combination Products, 2016
- Figure 8: Assessment by Route of Administration, 2016
- Figure 9: Assessment by Stage and Route of Administration, 2016
- Figure 10: Assessment by Molecule Type, 2016
- Figure 11: Assessment by Stage and Molecule Type, 2016

Buy Report @ [https://www.wiseguyreports.com/checkout?currency=one\\_user-USD&report\\_id=476527](https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=476527)

For more information or any query mail at [sales@wiseguyreports.com](mailto:sales@wiseguyreports.com)

Contact Us:

Norah Trent

+1 646 845 9349 / +44 208 133 9349

Follow on LinkedIn: <https://www.linkedin.com/company/wise-guy-research-consultants-pvt-ltd-?trk=biz-companies-cym>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.